Company news
Avacta Group Plc (LSE:AVCT) news
Avacta Group Plc news releases on 6ix. Latest, Oct 6, 2026: Avacta : Results of Placing and Subscription
Press releases & updates
Avacta : Results of Placing and Subscription
October 6, 2026
Capital Access Window - Avacta Group Plc
October 6, 2026
Results of Placing and Subscription
October 6, 2026
Proposed Fundraise to raise approximately £12.5m
October 5, 2026
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
September 30, 2026
Capital Access Window - Avacta Group Plc
September 30, 2026
Capital Access Window
September 30, 2026
Interim Results for Six Months to June 30, 2026
September 30, 2026
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
September 25, 2026
Avacta : Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
September 16, 2026
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
September 14, 2026
Accelerated Payment Convertible Bond Installment
September 4, 2026
Share Option Awards to Management Team at Avacta
September 1, 2026
Aberforth Geared Value & Income Trust Plc - Final Results
July 30, 2026
Avacta : Accelerated Amortized Payment of Convertible Bond Installment
July 9, 2026
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
July 8, 2026
Avacta : Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer
June 25, 2026
Year-to-date business update ahead of AGM
June 22, 2026
Oversubscribed Strategic Equity Fundraise of £9m
June 5, 2026
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
June 1, 2026
Avacta : Annual Report and Accounts for the year ending 31 December 2025
May 29, 2026
Unaudited Preliminary Full Year 2025 Results
May 19, 2026
Notice of Preliminary Results and Presentation
May 13, 2026
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
May 6, 2026
Avacta data AACR underline AVA6103 profile
April 21, 2026
Christina Coughlin - In Vivo 2026 Rising Leader
April 14, 2026
Q1 2026 Business Update
April 9, 2026
Avacta Announces Science Day 2026
April 8, 2026
First patient treated in Phase 1 trial of AVA6103
March 31, 2026
Result of Oversubscribed Fundraise
March 27, 2026
Proposed Fundraise to raise approximately £10m
March 26, 2026
Issue of Equity
March 26, 2026
Presentations of pre|CISION® Platform Candidates
March 17, 2026
Phase 1 study opening for AVA6103
March 16, 2026
PreCISION payload delivery advantage over ADC
February 24, 2026
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
February 24, 2026
Avacta to Participate in Conference March 2026
February 18, 2026
Appointment of CSO
February 9, 2026
Avacta appoints Francis Wilson as Chief Scientific Officer
February 9, 2026
Faridoxorubicin Program Clinical Updates
February 3, 2026
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
February 3, 2026
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
January 21, 2026
FDA Clearance of IND Application for AVA6103
January 21, 2026
Year-end trading update
January 20, 2026
Avacta Announces Year-end Trading Update
January 20, 2026
Appointment of Nominated Adviser & TVR
January 20, 2026
Avacta reports new AVA6103 pharmacology data
December 18, 2025
Faridoxorubicin Phase 1b SGC data
December 17, 2025
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
December 17, 2025
Preliminary Data in Faridoxorubicin Phase 1b Trial
December 8, 2025